Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/30 10:00:26 pm
118.13 USD   +0.73%
09/30 Celltrion doubtful on partnership with Pfizer
09/30 JOHNSON & JOHNS : Wall Street ends lower; Nasdaq Composite drops 1%
09/29 DOW MOVERS : Mrk, cat
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA Grants Priority Review to J&J's Bedaquiline Tuberculosis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
12/31/2012 | 04:02pm CEST
   By Nathalie Tadena 

The Food and Drug Administration has granted accelerated approval for Johnson & Johnson's (JNJ) drug to treat a drug-resistant form of tuberculosis.

The drug, bedaquiline, has faced concerns about an imbalance of deaths seen in clinical studies. J&J's Janssen Research & Development had asked the FDA for accelerated approval of bedaquiline, which is a type of temporary approval based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group--but the prescribing information for the treatment will include boxed warnings regarding increased risk of death.

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether bedaquiline played a role in deaths seen in clinical studies. While the FDA has said the safety data currently available for bedaquiline suggest the product appears safe, there is a potential for the highest dose of the product to cause a small change in the heart's rhythm. The FDA had said there wasn't enough data to rule out potential drug side effects on the liver and the heart. There were more deaths seen among patients being treated with bedaquiline although most of the deaths were attributed to the underlying disease.

The consumer group Public Citizen has strongly opposed the accelerated approval of bedaquiline because clinical trials showed the drug could be highly dangerous.

Only about 100 cases of drug-resistant TB are seen each year in the U.S. but the problem is more severe in typically poor countries outside the U.S.

Tuberculosis is a bacterial infection that mostly involves the lungs. It is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Bedaquiline is designed to work in a new way to treat TB and would be used with other drugs.

However, there is evidence that some forms of TB can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the worldwide control of tuberculosis."

Tuberculosis can be fatal if it's not properly treated.

Write to Nathalie Tadena at nathalie.tadena@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09/30 Celltrion doubtful on partnership with Pfizer
09/30 JOHNSON & JOHNSON : Wall Street ends lower; Nasdaq Composite drops 1%
09/29 JOHNSON & JOHNSON : Announces Agreement to Acquire Abbott Medical Optics
09/29 JOHNSON & JOHNSON : Advances Commitment to Improve Global Health and Well-Being
09/29 JOHNSON & JOHNSON : New Erythema Data Have Been Reported by Investigators at Joh..
09/29 JOHNSON & JOHNSON : Recent Findings from Johnson & Johnson Has Provided New Info..
09/29 DOW MOVERS : Mrk, cat
09/28 3D SIGNATURES : TSXV-listed 3D Signatures Names Jason Flowerday as New CEO
09/27 JOHNSON & JOHNSON : Two US companies eye Seagate land in Batu Kawan
More news
Sector news : Pharmaceuticals - NEC
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/30 Intra-Cellular Catatonic After Schizophrenia Fail
09/30 Medtronic's Artificial Pancreas Leads The Field
09/29 Buying Dividend Growth Stocks Without Looking; 17 Months Later.
09/29 PHILIP MORRIS INTERNATIONAL : Great Dividend Income Company With Inelastic Produ..
09/28 Obalon Therapeutics IPO May Inflate Company Prospects
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,65%
P/E ratio 2016 20,12
P/E ratio 2017 17,72
EV / Sales 2016 4,28x
EV / Sales 2017 4,01x
Capitalization 323 189 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 7,2%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.00%323 189
ROCHE HOLDING LTD.-12.52%214 851
NOVARTIS AG-11.00%207 776
PFIZER INC.4.93%205 444
MERCK & CO., INC.18.16%172 577
More Results